The abstract is read at the publisher; the summary is JClub's.
In streptozotocin-induced sinoatrial node dysfunction rats, efsubaglutide alfa increased heart rate to 372.76±11.06 vs 312.64±22.28 beats/min and shortened ADSNRT.
- Why it matters: Pacemaker therapy treats bradyarrhythmia without reversing sinoatrial node injury, and it is unknown whether long-acting GLP-1 receptor agonism can repair an injured SAN in SND.
- What they did: Rats underwent acute and chronic SND phases with efsubaglutide alfa, glycemic control, or a GLP-1R antagonist; outcomes included heart rate, intrinsic heart rate, heart rate variability, ADSNRT, SAN transcriptomics, and histology.
- The result: Efsubaglutide alfa improved heart rate and intrinsic heart rate acutely and chronically, reversed multiple SAN remodeling programs, reduced collagen and CCR2a+ infiltration, and effects were largely GLP-1R dependent.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.